OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
ModifiedBlue Cross Blue Shield - TexasPolicy N/A
Medical/Surgical Procedures Requiring Prior Authorization — Advanced Imaging, Molecular Genetic Testing, Transport and Surgical Procedures
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Texas policy alerts
Know when Blue Cross Blue Shield - Texas releases new policies or updates existing guidance.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
List of CPT/HCPCS codes and associated prior authorization management for advanced imaging/radiology services for Blue Cross Blue Shield of Texas fully insured and certain ASO groups; indicates services that may require prior authorization and which vendor manages authorization.
Policy Summary
PayerBlue Cross Blue Shield - Texas
PolicyMedical/Surgical Procedures Requiring Prior Authorization — Advanced Imaging, Molecular Genetic Testing, Transport and Surgical Procedures
Policy CodePolicy N/A
Change TypeMaterial updates to prior authorization lists and vendor routing
Effective Date01/01/2025
Next Review DateN/A
Key ActionObtain prior authorization from the designated vendor (typically Carelon or Alacura) for any listed CPT/HCPCS/U-code before ordering to avoid claim denial.
Addition of site of care to the medical necessity criteria for multiple imaging CPT codes effective 01/01/2025.
Category name changed from 'Non-Emergent Air Ambulance' to 'Medical Transportation' and services management for air ambulance codes changed from BCBSTX to Alacura (with exception for TRS Fully Insured Account: 212824 through 5/22/25).
Multiple molecular genetic and new U-codes and numerous CPT molecular/genetic codes were added to the prior authorization list with management assigned to Carelon or Alacura.
Prior authorization and upcoming site-of-care criteria
Prior authorization must be obtained and site-of-care requirements will apply starting 01/01/2025.
authorization_and_site_of_care: Prior authorization must be obtained via the managing organization listed (eg, Carelon) for any of the advanced imaging CPT codes enumerated in this policy; site-of-care criteria will be added to the medical necessity requirements effective 01/01/2025.01/01/2025
Per-code management and the effective date for addition of site-of-care are shown in the code list.
Prior authorization routing and requirement
Providers must submit prior authorization requests to the organization identified for each code.
Prior authorization routing: Provider must submit prior authorization requests for the listed CPT and HCPCS codes to the managing organization identified next to each code (examples include Carelon, BCBSTX, and Alacura).
Per-code vendor assignment is indicated in the code listing; follow the designated manager for submission.
Prior Authorization Required
Coverage (or consideration for coverage) for these services is contingent on obtaining prior authorization routed to the designated manager.
Prior authorization requirement: Prior authorization must be obtained for the listed home infusion, medical transportation (air ambulance), and molecular genetic testing codes prior to performing or billing the service.
Some transport codes list Alacura as manager (with TRS exception through 5/22/25); many molecular/genetic codes list Carelon.
Prior authorization coverage stance
Ordering of the listed molecular genetic and molecular pathology tests requires prior authorization to be considered for coverage.
prior_auth_required: Prior authorization is required for ordering any of the listed CPT 813xx or 814xx molecular genetic/molecular pathology tests; authorization must be obtained before testing to be considered for coverage.
The code listings provide test descriptors and indicate Carelon as the authorization manager for these codes.
Panel gene-content coverage criteria
Coverage for specified hereditary-condition panels requires that the performed panel include the minimum gene content identified for that indication.
Panel composition requirement: For the hereditary disorder indications listed, genomic sequence analysis panels must include sequencing (or duplication/deletion analysis where specified) of the minimum genes identified for that panel (example: aortic dysfunction/dilation panels must include at least 9 specified genes including FBN1, TGFBR1, TGFBR2, COL3A1, MYH11, ACTA2, SLC2A10, SMAD3, MYLK).minimum gene list as specified per CPT entry
Exact gene lists and minimum counts are provided alongside each CPT code in the code table.
Coverage conditional on panel specification and prior authorization
Coverage is conditional on both panel content matching the listed panel definition and prior authorization being obtained through the designated administrator.
Panel match and authorization: The ordered test corresponds exactly to a listed CPT/PLA/HCPCS code with the panel descriptor and minimum gene-count requirements specified in this policy AND prior authorization is obtained through Carelon (or other designated manager where noted).
Many entries list minimum gene counts (eg >=5, >=10, >=60) or specific required genes; the performed panel must match the listed descriptor.
Prior Authorization Requirement for Listed Molecular Genetic Tests
The proprietary (PLA) and other molecular genetic test codes listed require prior authorization to be considered for coverage.
Prior authorization requirement: Orderers must obtain prior authorization from Carelon for any listed PLA, U-, or other molecular genetic/proprietary test code prior to performing the test to ensure the test will be considered for coverage.
Each listed PLA/U-code includes a test descriptor and Carelon is identified as the authorization manager for these entries.
Prior authorization criteria
Prior authorization is required for the U-code (and related) molecular genetic/genomic tests before ordering.
Authorization requirement: Prior authorization must be obtained for any of the U-coded molecular genetic/genomic tests enumerated in this section before ordering or performing the test.
Each U-code in the list maps to a specific test description; Carelon is listed as the administrator for the U-code entries.
Prior authorization for listed molecular genetic tests
Listed molecular genetic laboratory tests (U- and J-codes) are subject to prior authorization through Carelon.
Prior authorization requirement: Prior authorization must be obtained through Carelon for each listed U-code or J-code molecular genetic test before billing or performing the test.
This section enumerates U- and J-codes and their descriptors; clinical medical necessity criteria are not detailed here.
The molecular genetic lab tests and other listed codes require prior authorization as indicated.
Listed tests: The molecular genetic laboratory tests and codes enumerated in this section require prior authorization through the designated administrator (Carelon) to be considered for coverage; entries provide clinical context for each test (eg oncology, transplant, obstetrics).
Per-code descriptors and manager assignments appear in the coding section.
Prior authorization required for listed items
All procedure and test codes enumerated in this section are subject to prior authorization as indicated.
Listed procedures/tests: All procedure and test codes enumerated in this portion of the document require prior authorization as indicated (many entries identify Carelon as the administrator); obtain authorization prior to providing services to avoid denial.
This block is a code-list level requirement; clinical indication details beyond code descriptors are contained in the code entries.
The presence of codes on this list does not necessarily indicate coverage under a member's benefits contract. Member benefits vary by product and group; consult the member benefit booklet or contact customer service to determine whether a specific procedure or test is covered for the member in question. Fully insured groups may have specific prior authorization requirements and exceptions noted in the listing.
This excerpt is a code-level prior authorization listing and does not contain per-procedure clinical coverage criteria. It identifies CPT/HCPCS codes (for example, cardiac MRI and CT heart procedures) and the designated prior authorization administrator for each code; providers must obtain authorization where required and follow the submitting vendor’s process.
The document segment does not provide clinical coverage criteria or explicit exclusions; rather, it enumerates procedure codes (including SPECT/PET myocardial perfusion and related nuclear medicine codes) that require prior authorization and names the managing organization for those codes.
This section includes operational notes about category and vendor management changes. Effective 01/01/2025 the category name was updated from “Non‑Emergent Air Ambulance” to Medical Transportation, and services management moved from BCBSTX to Alacura, with a TRS fully insured account exception managed by BCBSTX through 05/22/2025 and transitioning to Alacura effective 05/23/2025.
The chunks in this portion are primarily code listings for molecular genetic and molecular pathology CPT codes requiring prior authorization; they do not contain explicit medical necessity criteria within the excerpt. Providers should obtain prior authorization as indicated and submit required documentation to the designated manager.
Several molecular pathology/molecular genetic codes in the list are flagged with retirement lifecycle notes. For example, some entries show 'Retire Effective 04/01/2025' for specified codes; these retirement flags should be tracked because they may change how authorizations or billing are handled after the effective retirement date.
Retirement examples include codes such as 81433, 81436, and 81438 which are noted as 'Retire Effective 04/01/2025' in the listing. Treat such entries as lifecycle notes that may affect future authorization routing or code validity and consult payer guidance at or before the retirement effective date.
This excerpt is a prior‑authorization code list and does not set out explicit exclusions; it lists services that require authorization and names the administering organization for those entries.
Some proprietary U‑codes and other test codes are marked with 'Retire Effective' dates (for example, 0380U, J0428U, 0448U, 0456U, 0396U). Codes with 'Retire Effective' flags may be removed or replaced on the payer’s authorization lists after the stated date and therefore can change authorization handling or billing workflows.
The available excerpt does not include explicit exclusions for the listed molecular genetic and molecular pathology CPT codes; it provides per‑code entries and identifies the required prior authorization process.
These chunks list codes requiring prior authorization and do not state explicit exclusions. Clinical coverage decisions remain subject to individual member contract terms and medical necessity determinations.
This code list segment does not specify conditions that are explicitly ‘not medically necessary.’ It functions as an authorization requirement list; medical necessity determinations (including potential NMN findings) must be made using the payer’s medical policy and member benefit terms.
Fallback/unknown chunk indices in the planner correspond to code‑list material in the source. The excerpt remains a prior authorization list without embedded clinical exclusion rules — consult the full medical policy for indication‑specific coverage rules.
No 'not medically necessary' statements are specified in these chunks; the document portion is a list of codes that require prior authorization. Providers should rely on detailed medical policies for determinations of medical necessity.
The molecular genetic code listings in this excerpt do not include explicit 'not medically necessary' language; instead, they enumerate tests that require prior authorization through the designated administrator.
Transmitter cable for cochlear implant replacement
Provider Actions — Submitting Prior Authorization and Documentation
Prior Authorization
Prior Authorization Required
Prior authorization is required for the molecular genetic/proprietary PLA tests listed in this document. Providers must obtain prior authorization before ordering these tests; failure to obtain prior authorization may result in claim denial or adverse payment action.
PLA molecular genetic tests (U-codes and other proprietary PLA codes) listed throughout the Medical Surgical Procedures Requiring Prior Authorization section require prior authorization and are managed by Carelon as indicated.
Presence of a code on the prior authorization list does not guarantee coverage under the member's benefits contract; coverage is determined by the member's specific benefit booklet or contract.
Some codes in the molecular genetic section are marked as retired or retiring (examples: CPT 81433, 81436, 81438 marked Retire effective 04/01/2025; select U-codes and others list add/retire effective dates). Providers should note code lifecycle changes when submitting requests.
Denial risk: Claims submitted without required prior authorization for listed molecular genetic tests, PLA codes, or other listed CPT/HCPCS codes may be denied.
The policy file is a searchable PDF. Providers should use search to locate specific codes and descriptors when preparing authorization requests.
Authorization submission destination: Prior authorization requests for codes managed by a vendor (for example, Carelon or Alacura) must be submitted to the named vendor per that vendor's submission processes and channels.
Prior Authorization — Modalities and Scope
Note
Note
Note
Note
Note
Note
Note
Contrast and Sequence Coding Notes
Note
Note
Note
Note
Background — Document Scope and Content
This policy excerpt enumerates CPT and HCPCS procedure codes across nuclear medicine (SPECT, PET), radiopharmaceutical studies, CT breast, quantitative MRI tissue composition and a broad range of molecular and genetic laboratory tests that require prior authorization. Many imaging and molecular test codes identify Carelon as the designated prior authorization manager and include effective dates or operational notes (for example, site‑of‑care additions effective 01/01/2025).
Definitions and Abbreviations
Carelon — authorization manager
Carelon as authorization managerCarelon is identified repeatedly as the prior authorization reviewer/administrator for the molecular genetic and many imaging codes listed
Examples of managed CPT/PLA/U codesCarelon is listed next to numerous CPT (e.g., 813xx/814xx), PLA and U-code entries indicating prior authorization routing to Carelon
Submit to CarelonProviders must submit prior authorization requests for the listed tests and procedures to Carelon where shown
Tomographic (SPECT) with CT
DefinitionSPECT with concurrently acquired CT transmission scan for anatomical localization and attenuation correction
ApplicationUsed for tomographic radiopharmaceutical localization and anatomical review (examples: 78832 descriptions)
Covered Indications — When Authorization Applies
Advanced imaging procedures — prior authorization and site-of-care effective 01/01/2025
Advanced imaging CPT codes listed in this policy require prior authorization; site-of-care additions become effective 01/01/2025.
advanced_imaging_codes: Prior authorization is required for the advanced imaging CPT codes listed in this policy (CT, CTA, MRI, MRA and related codes); per-code management is shown as Carelon and site-of-care requirements will be incorporated effective 01/01/2025.01/01/2025
Follow the designated authorization routing and include site-of-care information once the 1/1/2025 medical necessity updates are in effect.
Request for any listed advanced imaging procedure
Requesting any advanced imaging procedure shown in the list requires prior authorization.
request_for_listed_procedure: When requesting any of the advanced imaging procedures enumerated in this policy, the provider must obtain prior authorization from the listed manager (eg, Carelon) before scheduling or performing the study.
Policy Summary
PayerBlue Cross Blue Shield - Texas
PolicyMedical/Surgical Procedures Requiring Prior Authorization — Advanced Imaging, Molecular Genetic Testing, Transport and Surgical Procedures
Policy CodePolicy N/A
Change TypeMaterial updates to prior authorization lists and vendor routing
Effective Date01/01/2025
Next Review DateN/A
Key ActionObtain prior authorization from the designated vendor (typically Carelon or Alacura) for any listed CPT/HCPCS/U-code before ordering to avoid claim denial.
Submit prior authorization to the listed vendor: when an entry identifies Carelon (or Alacura/BCBSTX for certain codes), route requests to that organization. For example, molecular genetic entries indicate Carelon as the authorization administrator.
Authorization channel: Submit authorizations via the vendor's accepted channels (vendor portal, fax, or phone) as specified by the vendor; follow the vendor's documentation and submission instructions.
Route prior authorization to the designated manager: site-of-care or service-management changes (e.g., transition of A0430/A0435 to Alacura effective 1/1/25, TRS account exceptions) require routing to the manager shown for the specific member/account.
Documentation requirements: Include relevant clinical documentation, test type, specimen source (e.g., FFPE tumor tissue, plasma, whole blood), panel composition (when applicable), and indication to support medical necessity.
Test-specific documentation: For genomic sequence analysis panels, document the genes included (minimum gene lists where specified), sequencing method, and specimen. For U-code entries and PLA tests, include report type and algorithm descriptions when available.
Where to submit prior authorization: Use the authorization administrator shown next to each code (e.g., Carelon for most molecular genetic CPT/PLA/U-codes; Alacura for select medical transportation codes; BCBSTX for specified services).
Code lifecycle note: Monitor effective and retire dates shown in the list (e.g., codes added with future effective dates or codes retired effective 04/01/2025) because these affect authorization routing and coverage determination.
Documentation Required
Documentation Requirements
Providers must include test type, specimen, panel gene composition (when required), and any algorithm/report descriptors in the authorization request. When a panel requires sequencing of a specified minimum gene list, document that the panel meets the minimum gene set described in the policy.
Document test type and specimen (e.g., FFPE tumor tissue, plasma cell-free DNA, whole blood, buccal swab).
For genomic panels that specify a minimum gene list (examples in 81410, 81430, 81432, etc.), include confirmation the panel includes the named genes.
Include clinical indication and relevant prior test results that support medical necessity for the requested test.
Denial Risk
Denial Risk for Missing Prior Authorization
Claims for listed CPT/HCPCS/PLA/U-codes may be denied if prior authorization is not obtained when required. Providers should verify authorization status before performing or billing for services.
Denial risk applies across advanced imaging, molecular genetic tests, home infusion, medical transportation, musculoskeletal/spine surgery codes, and other categories listed in this document.
Retired codes (e.g., 81433, 81436, 81438 retire effective 04/01/2025) may affect authorization processing or submission — verify current code status at time of request.
Prior Authorization
Authorization Submission Destination
Authorization submissions must be directed to the administrator identified next to each code entry. Carelon is the primary prior authorization administrator for the majority of advanced imaging and molecular genetic tests in this list; Alacura manages specified medical transportation codes; BCBSTX manages select services and Fully Insured account exceptions.
Carelon: submit authorization requests per Carelon processes for the CPT/HCPCS/PLA/U-codes that list Carelon as Managed By/Authorization Administrator.
Alacura: submit prior authorization requests for A0430/A0435 and other medical transportation codes now managed by Alacura (note TRS Fully Insured account exceptions and effective dates).
BCBSTX: some services remain managed by Blue Cross Blue Shield of Texas (BCBSTX) — follow the instruction in the code row when BCBSTX is listed as manager.
If a code entry lists a vendor and an effective date or account exception, route the request according to the effective/account-specific instructions.
Note
Code Lifecycle Note
The policy includes code lifecycle information such as add and retire dates. Providers should confirm code validity and effective/retire dates before submitting authorizations to avoid processing issues.
Examples: certain CPT codes are marked 'Retire Effective 04/01/2025' (e.g., 81433, 81436, 81438); other codes show future add effective dates (e.g., select U-codes with Add effective 07/01/2025 or 10/01/2025).
If a code is retired, consult the vendor and payor guidance for replacement codes or alternative submission instructions.
Note
Note
Note
Note
Note
Note
Note
Authorization noteEntries for SPECT with CT list Carelon as the managing authorization vendor where applicable
Procedure descriptionQuantitative magnetic resonance for analysis of tissue composition (fat, iron, water content) with multiparametric acquisition
CPT mappingCodes 0648T/0649T describe QMR tissue composition analysis; 0649T is obtained with diagnostic MRI of same anatomy
Authorization vendorThese QMR CPT entries indicate Carelon as the authorization manager in the listing where present
Levels 1–4 describe complexity
Procedural complexity levelsMolecular pathology procedure levels 1–4 describe increasing analytic complexity (Level 1 single variant → Level 4 single exon sequencing or >10 amplicons)
Clinical examplesLevel definitions include examples spanning single variant detection, 2–10 SNPs or dynamic mutations, >10 SNPs/complex rearrangements, and multi‑amplicon/exon sequencing
Level examples and scopeHigher molecular pathology procedure levels (Levels 3–8) map to analyses such as >10 SNVs, full gene sequencing, and multi‑exon/large exon count analyses as exemplified in CPT 81402–81408 listings
Use in codingThese level descriptors are used to categorize molecular pathology procedures for authorization and coverage routing
Genomic Sequence Analysis Panel — definition and sequencing requirements
DefinitionGenomic sequence analysis panel: a multi-gene sequencing panel targeting a listed set of genes for a specific hereditary disorder or neoplasm, often requiring sequencing of a minimum number of genes specified per code
Sequencing requirementMany CPT entries require sequencing of specified minimum genes and/or duplication/deletion analysis to meet the panel definition
Specimen typesPanels are described for various specimen types (eg, FFPE tumor tissue, cfDNA) depending on the code entry
mRNA gene expression profiling — definition and purpose
Definition and purposemRNA gene expression profiling measures mRNA expression of a defined gene set (eg by RT‑PCR or microarray) to generate algorithmic risk scores or classifications for oncology and other applications
Example usesBreast and other oncology recurrence or risk scoring tests (CPT 81518–81523, 81540 etc.) use mRNA expression profiling on FFPE or fresh tissue
FFPE — Formalin‑Fixed Paraffin‑Embedded specimen
Specimen typeFormalin-Fixed Paraffin-Embedded (FFPE) tumor tissue is referenced for comprehensive genomic profiling and many molecular assays
Common tests using FFPELarge NGS tumor panels and gene expression microarrays are described as using FFPE tissue in multiple U-code/CPT entries
Carelon — prior authorization reviewerCarelon is designated as the prior authorization reviewer/processor for numerous listed CPT, PLA, U‑ and J‑codes across imaging and molecular testing sections
Submission routingProviders should submit authorization requests to the vendor named next to each code (Carelon for most molecular/genetic tests)
FFPE — FFPE tumor tissue for molecular assays
FFPE tumor tissue useFFPE tumor tissue is used for comprehensive genomic profiling and is specified as the sample type for multiple U‑code and CPT panel tests
Panel examplesExamples include FFPE-based targeted genomic panels (eg 0334U, 0473U, 0444U) that interrogate large gene sets and require authorization
cfDNA — cell‑free circulating DNA
DefinitionCell-free circulating DNA (cfDNA) refers to plasma-derived tumor DNA used for targeted genomic panels and minimal residual disease (MRD) assessment
ExamplescfDNA panels (eg 0326U, 0306U/0307U, 0242U) are listed with large gene counts and used for MRD or comprehensive cfDNA profiling
Carelon listed repeatedlyCarelon appears as the prior authorization administrator for the majority of molecular genetic, proprietary, and many imaging codes in the list
Provider actionSubmit prior authorization requests to Carelon for codes where Carelon is identified
U‑code / J‑code — proprietary lab test tracking codes
U‑code / J‑code purposeCMS-assigned U‑ and J‑codes identify proprietary laboratory tests and are used in the document to list specific molecular/genomic tests requiring prior authorization
ExamplesMultiple U‑codes (eg 0314U, 0326U, 0334U) and J‑codes (eg J0266U, J0400U) are enumerated with test descriptions and Carelon routing
Donor‑derived cell‑free DNA (dd‑cfDNA)
dd‑cfDNA useDonor‑derived cell‑free DNA (dd‑cfDNA) quantification is reported as a percentage to determine probability of organ rejection (listed under 0543U/0544U/0549U and S38xx entries)
AuthorizationThese dd‑cfDNA tests are managed by Carelon and include future 'Add effective' flags in the list
S38xx molecular/genetic test codes
S38xx series roleS38xx HCPCS codes correspond to molecular/genetic testing (transplantation and other genetic tests) listed as requiring prior authorization
ExamplesEntries S3846–S3854 are dd‑cfDNA or related molecular tests with Carelon routing and 'Add effective' flags
Musculoskeletal/spine CPT codes
Code range and specialtyCPT codes in the 0xxxx–2xxxx series in this section primarily represent musculoskeletal and spine surgery procedures that require prior authorization
ExamplesIncluded examples: 0627T–0630T (intervertebral cellular injections), vertebral/arthrodesis instrumentation codes, and other spine surgical CPTs
This applies across modalities included in the code list.
Certain echocardiography, PET, SPECT and other nuclear medicine procedures listed require prior authorization.
echocardiography_pet_spect
echocardiography: Transthoracic and transesophageal echocardiography codes listed (eg 93303-93306, 93350-93352) require prior authorization per the listing.
pet_spect: PET and SPECT imaging codes (eg 78811-78816, 78451-78454, G0219, G0235, G0252) require prior authorization per the code entries.
PET and advanced MRI studies
PET imaging and select advanced MRI studies listed require prior authorization.
pet_advanced_mri: PET imaging codes (G0219, G0235, G0252) and advanced MRI/MR angiography codes listed require prior authorization; requests must be submitted to the manager indicated for each code.
G0219 is noted for melanoma non-covered indications in the list; follow per-code guidance.
Spine and related musculoskeletal procedures requiring authorization
Spine and related interventional/surgical procedures require prior authorization when billed under the listed CPT codes.
spine_musculoskeletal_authorization: Interventional spine procedures (eg vertebroplasty, kyphoplasty, percutaneous injections, and percutaneous biologic injectates) and enumerated spine surgical CPT codes require prior authorization prior to surgery or intervention as shown in the code list; authorization routing is to the manager listed for each code (eg, Carelon).
Some newer procedure codes (eg 0627T–0630T) have add-effective dates; follow the policy and code-level effective dates.